Serious adverse events · adults with advanced cancer and cancer‐related fatigue
1 finding from 1 review
Serious adverse events · adults with advanced cancer and cancer‐related fatigue
1 finding from 1 review
Serious adverse eventsg · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
Low dose naldemedine showed no clear difference in serious adverse eventsg compared with higher doses (low certainty).
1 finding from 1 review
Serious adverse events · people with cancer and receiving palliative care with opioid‐induced bowel dysfunction
1 finding from 1 review
Serious adverse eventsg · people with cancer irrespective of whether they were receiving palliative care opioid‐induced bowel dysfunction
It is very uncertain whether naloxone + oxycodone prolonged release tablets changes serious adverse eventsg compared with oxycodone prolonged‐released tablets (very low certainty).
1 finding from 1 review
Serious adverse eventsi · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
Methylnaltrexone may leads to lower serious adverse eventsi compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse eventsh · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
Naldemedine showed no clear difference in serious adverse eventsh compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · Patients with COVID‐19
1 finding from 1 review
Serious adverse events ( · adults with sickle cell disease in a vaso‐occlusive crisis
1 finding from 1 review
Serious adverse events · adults with chronic neuropathic pain
1 finding from 1 review
Serious adverse events · children with acute postoperative pain
1 finding from 1 review
Serious adverse events · cancer patients
Olanzapine showed no clear difference in serious adverse events compared with placebo/no treatment (low certainty).
1 finding from 1 review
RR 2.46 [0.48, 12.55]
Studies not reported
Low
Serious adverse events · cancer patients
It is very uncertain whether olanzapine changes serious adverse events compared with NK1 antagonist (very low certainty).
1 finding from 1 review
RR 0.33 [0.02, 7.32]
Studies not reported
Very low
Serious adverse events · adults with postherpetic neuralgia
1 finding from 1 review
Serious adverse events · adults with neuropathic pain
1 finding from 1 review
Serious adverse events · aged 18 years and older undergoing elective surgery at any surgical site
1 finding from 1 review
Serious adverse events · aged 18 years and older undergoing elective surgery at any surgical site
1 finding from 1 review
Serious adverse events · adults with neuropathic pain
1 finding from 1 review
Serious adverse events · adults with episodic tension‐type headache
1 finding from 1 review